Home > Neurology > MTIS 2020 > Contents > Long-term onabotulinumtoxinA improves quality of life in migraine

Long-term onabotulinumtoxinA improves quality of life in migraine

Presented By
Dr Guy Boudreau, Centre Hospitalier Universitaire de Montréal, Canada
Conference
MTIS 2020
Trial
PREDICT
  Real-world data from the PREDICT trial demonstrated that long-term onabotulinumtoxinA treatment improved health-related quality of life of patients with chronic migraine. In addition, onabotulinumtoxinA treatment reduced headache days, with high physician and patient satisfaction [1]. Chronic migraine can affect health-related quality of life and daily functioning, resulting in social and economic burden. PREDICT was a 2-year, multicentre, prospective, observational study in Canadian adults who were naïve to botulinum toxins for chronic migraine. The aim was to assess real-world long-term effects of onabotulinumtoxinA on quality of life in this patient population. OnabotulinumtoxinA treatment was recommended for injection every 12 weeks, up to 7 treatment cycles. A total of 184 partici...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on